VIDEO: Updated POLARIX results presented at ASH 2024
Click Here to Manage Email Alerts
SAN DIEGO — Paolo Caimi, MD, spoke with Healio about the latest results from the POLARIX trial presented at ASH Annual Meeting and Exposition.
The findings presented at the meeting included 5 years of follow-up data assessing the use of polatuzumab vedotin (Polivy, Genentech) with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) in patients with intermediate or high-risk diffuse large B-cell lymphoma.
Caimi, a physician and clinical investigator at Cleveland Clinic, told Healio that the findings showed “that the progression free survival benefit with [Pola-R-CHP] persists, even though it’s a little bit smaller than what it was originally reported.”
Reference:
Salles G, et al. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Collapse
Healio Interviews
Click Here to Manage Email Alerts